Canaccord Genuity maintains BridgeBio Pharma at Buy, raises price target to $108 from $106

What happened

Canaccord Genuity kept its Buy rating on BridgeBio Pharma and raised its price target to $108 from $106, a 1.9% increase. The new target implies 44.1% upside from the October 30 closing price of $74.95. Five recent analyst targets ranged from $88 to $120.

Confirmed

Global impact / market context

The higher target signals Canaccord sees more potential share-price appreciation, but it is an analyst estimate rather than a company result or guarantee. If investors act on the rating, their demand for BridgeBio shares could shift; the article reports no actual market reaction.

Analyst inference

Recent analyst views are spread across a broad range: five targets over the past 30 days ran from $88 to $120, while ratings included Buy, Overweight, and Neutral. That variation shows analysts differ on BridgeBio’s prospects; the article gives no underlying reasons.

Confirmed

What to watch

1. Whether other analysts change their ratings or price targets, since the recent $88-to-$120 range shows differing views and could influence investor expectations for BridgeBio shares. Analyst inference
2. Whether BridgeBio reports company developments that could support or challenge the analyst optimism; no clinical, regulatory, revenue, or cost updates are included in this article. Analyst inference
3. Whether the share price moves toward or away from Canaccord’s $108 target; the stated 44.1% upside is measured from the October 30 close, not a forecast guarantee. Analyst inference

Evidence

• Original source link unavailable